Amgen Inc. Files 8-K on Financials

Ticker: AMGN · Form: 8-K · Filed: May 1, 2025 · CIK: 318154

Amgen INC 8-K Filing Summary
FieldDetail
CompanyAmgen INC (AMGN)
Form Type8-K
Filed DateMay 1, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-k

Related Tickers: AMGN

TL;DR

AMGN filed an 8-K on May 1st detailing financial results and condition.

AI Summary

Amgen Inc. filed an 8-K on May 1, 2025, reporting on its results of operations and financial condition, and including financial statements and exhibits. The filing details its corporate information, including its principal executive offices located at One Amgen Center Drive, Thousand Oaks, California.

Why It Matters

This filing provides investors with crucial updates on Amgen's financial performance and operational status, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial reporting filing with no immediate negative or positive news indicated.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Amgen Inc.?

The primary purpose is to report on Amgen Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.

On what date was this 8-K report filed?

The report was filed on May 1, 2025.

Where are Amgen Inc.'s principal executive offices located?

Amgen Inc.'s principal executive offices are located at One Amgen Center Drive, Thousand Oaks, California 91320-1799.

In which state was Amgen Inc. incorporated?

Amgen Inc. was incorporated in Delaware.

What is the SEC file number for Amgen Inc.?

Amgen Inc.'s SEC file number is 001-37702.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 1, 2025 regarding AMGEN INC (AMGN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing